Clostridium Butyricum
Phase 3Small molecule
Clostridium Butyricum is one of 78 small molecule programs targeting Neoadjuvant Immunotherapy. It is currently in Phase 3.
4
Indications
7
Total Trials
5
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
268 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Telisotuzumab Adizutecan
AbbViePhase 3
TAS 102
Taiho Oncology, Inc.Phase 3
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Phase 3
IBI363
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Iron Isomaltoside
TThomas Jefferson University
Phase 3
Clostridium Butyricum
XXijing Hospital of Digestive Diseases
Phase 3
Tucidinostat
CChipscreen Biosciences, Ltd.
Phase 3
Mfolfoxiri
DDominik Paul Modest
Phase 3
TQB2102
CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
HR070803
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Helicobacter Pylori Eradication1 trial
Urothelial Carcinoma1 trial
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06696742·60 enrolled
Probiotic Intervention1 trial
Colorectal Cancer1 trial
2 more indications
Dyspepsia1 trial
Neoadjuvant Immunotherapy1 trial
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05914389·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Clostridium Butyricum. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details